Infusion Nursing Notes by Nufactor provides education, resources and support to promote successful patient therapy within the infusion nursing community.

Understanding TREMFYA® (Guselkumab): A Targeted Treatment for Inflammatory Conditions

16. January 2026 Leanne Edwards Disease States, Nursing Support (0)
TREMFYA® is a biologic therapy known as a monoclonal antibody. It works by targeting and blocking interleukin-23 (IL-23), a key player in inflammation. When IL-23 is overactive, it can contribute to chronic diseases of the skin, joints, and digestive tract. By blocking IL-23, this therapy helps reduce inflammation and prevent flare-ups, thereby improving quality of life. [More]

Anaphylaxis Protocols in Home Infusions: Safety Guidelines for Nurses

11. November 2025 Marianna Herrera (0)
Home infusion nursing brings the unique responsibility of providing high-quality care outside the traditional clinical environment. In the home setting nurses are a "One Man Team", unlike the hospitals that provide rapid response teams at a push of a button. While serious adverse drug reactions (ADRs) are rare, anaphylaxis can occur suddenly and without warning, requiring immediate recognition and decisive action. Nufactor patients are staffed with nurses who must undergo vetting and skills assessment prior to providing care to patients. This is done to ensure they are fully prepared to not only safely and effectively complete the infusion but also recognize any adverse drug reactions and be prepared to intervene accordingly. [More]

Tips and FAQs About Ordering and Organizing Infusion Supplies

30. September 2025 Candy Finley Infusion Basics, Nursing Support (0)
Discover best practices to keep you and your patient prepared and organized for infusion day. The most important thing you will need in the home as a field nurse are proper supplies. If anything is missing, it may delay the infusion or cause it to be rescheduled. Nufactor provides all ancillary supplies a nurse needs to complete an infusion except for a stethoscope, blood pressure cuff, and thermometer, which are to be provided by the nurse. Upon start of care (SOC), the pharmacy will send a small quantity of extra supplies in a labeled back up kit. This helps to ensure the infusion can be completed if extra supplies are needed unexpectedly. The back up kit also contains items that may only be needed in specific situations such as rate flow tubing or N95 masks. If ordered, an anaphylaxis kit is also provided at SOC. [More]

Managing Infusion Side Effects - Who to Call and When

31. July 2025 Marianna Herrera IVIG Essentials (0)
Timely recognition and communication of side effects during IVIg or SCIG therapy is essential to patient safety and treatment adherence. Reactions vary by patient and can range from mild to severe. As the nurse, you are often the only clinician physically present during infusions—your assessments and communication are critical in managing the patient’s care. If side effects are not managed appropriately and tolerability becomes an issue, the patient may want to stop therapy, which could impact the management of their condition. The following is a guide to help you determine who to call and when. [More]

Practical Strategies for Patients and Caregivers to Minimize Reactions with Subcutaneous Immune Globulin (SCIG)

30. June 2025 Candy Finley Infusion Basics, Nursing Support (0)
Providing clear and concise information for patients receiving subcutaneous immune globulin (SCIG) therapy, is of utmost importance. SCIG treatments can be life-changing for people with immune deficiencies and autoimmune conditions; localized site reactions are anticipated and generally well-tolerated and should not be considered a contraindication to treatment continuation. In this blog, I will share some practical strategies to help minimize these reactions and hopefully improve the overall experience for patients and caregivers. Typical localized site reactions include but are not limited to burning, itching, redness, swelling, and pain to injection sites. These reactions should minimize over time once the body gets used to the drug. [More]

HYQVIA® 10% — Learn About Expanded FDA-Approval for Treating PIDD and CIDP

23. May 2025 Marianna Herrera Nursing Support (0)
HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] Solution, for subcutaneous administration was first FDA-approved in 2014 for primary immunodeficiency (PIDD) in adults. In 2023, HYQVIA® received expanded FDA-approval in PIDD to include pediatric patients aged 2-16. In 2024 HYQVIA® received FDA-approval for maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP). [More]

Hizentra® 20% Prefilled Syringe Administration: Best Practices and Administration Guidelines

28. April 2025 Candy Finley (0)
Hizentra® is indicated for Primary immunodeficiency (PI) in adults and pediatric patients 2 years of age and older and maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP). Upon initial FDA approval, Hizentra® was commercially available in vials only. The manufacturer of Hizentra®, CSL Behring, has since transitioned from vials to prefilled syringes (PFS). Hizentra® is available in 1 gm/5 mL, 2 gm/10 mL, 4 gm/20 mL, and 10 gm/50 mL sizes. The recommended Hizentra® dose and volume, rate per SC site and volume per SC site are typically greater in CIDP compared to PI. [More]

Payers

IG & Coagulation Resources
Site of Care Savings

Support

Contact Us
Refer a Patient
Become a Patient

About Us

Mission & Vision
Core Values
Careers

Nufactor

Service Model
Accreditation
IgCP, IgCN, CSP

Nufactor, Inc. is the specialty pharmacy subsidiary of FFF Enterprises.

Nufactor Corporate
Headquarters
44900 Winchester Road
Temecula, CA 92590

(800) 323-6832

Home • Terms • Privacy Statement • • About Us • Careers
©2022 Nufactor